79 



tine. We have yet to visit any smokeless tobacco company and 

 begin a face-to-face dialogue, but I would welcome that and I would 

 certainly reauest the smokeless tobacco industry to produce for the 

 Agency all documents relating to nicotine, nicotines physiological 

 and pharmacologicEd effects and any documents relating to control 

 and manipulation of nicotine. I welcome that. I have not seen 

 them, but we would ask them to do so. 



Mr. Franks. I am sure they would be happy to provide that in- 

 formation, but getting back to your earlier point, obviously when 

 you are talking about smoking tobacco, and most of your comments 

 were obviously directed toward that industry, cigarettes, is there 

 anything that you can mention at this point that would be applica- 

 ble to the smokeless tobacco industry? 



Mr. Kessler. Sure. Andrew, do you have the chart on the "grad- 

 uation process." 



Mr. Franks. Maybe I shouldn't be asking this question. 



Mr. I^SSLER. This is a — actually part of a — I guess it was a pro- 

 motional campaign document, an advertising campaign document, 

 a company document that came out that we saw 



Mr. Franks. Do we have a copy of this in here? 



Mr. Kessler. It was attached to my previous testimony and we 

 would be happy to submit that. I would be happy to bring it closer. 

 Congressman, if you want. 



Mr. Franks. I can't see it. 



[The chart referred to follows:] 



